Abstract

ObjectiveTo analyze the effect of microRNA‐22 on autophagy and proliferation and to investigate the underlying molecular mechanism of osteosarcoma cell chemotherapy sensitivity.MethodsMG‐63 cells were divided into four groups, including a control group, a negative control (NC) group, a cisplatin group, and a cisplatin + miR‐22 group. Proliferation of MG‐63 cells that had been treated with cisplatin and transfected with miR‐22 mimics was determined using MTT assay and colony formation assay. We assessed the degree of autophagy using flow cytometry through cellular staining of the autophagy lysosomal marker monodansylcadaverine (MDC). The effect of microRNA‐22 on autophagy was observed along with the expression levels of Beclin1, LC3, metadherin (MTDH) and ATG5 by western blot and quantitative reverse transcription polymerase chain reaction (qRT‐PCR). Luciferase reporter assay revealed the targeted binding site between miR‐22 and the 3′‐untranslated region (3′‐UTR) of MTDH mRNA. Western blot and qRT‐PCR were used to explore the level of MTDH in the control group, the NC group, the cisplatin group, and the miR‐22 group for 6, 12, and 24 h.ResultsIn the in vitro study, the MTT results indicated that the MG‐63 cells with overexpression of miR‐22 exhibited a significant decline in the proliferation capacity compared with the control group (0.513 ± 0.001, P < 0.0005). Similar to the MTT results, MG‐63 cells that were transfected with miR‐22 mimic (101.0 ± 10.58) formed fewer colonies compared with the cisplatin group (129.7 ± 4.163). MDC staining revealed that miR‐22‐overexpressing osteosarcoma (OS) cells treated with cisplatin showed a significant decrease in the expression of autophagy (7.747 ± 0.117, P < 0.0001). Our data revealed that miR‐22 could regulate not only autophagy but also proliferation in the chemosensitivity of osteosarcoma cells. We found that miR‐22 sensitized osteosarcoma cells to cisplatin treatment by regulating autophagy‐related genes. In addition, Luciferase Reporter Assay revealed that miR‐22 negatively regulated autophagy through direct targeting of MTDH. We performed western blot analysis to detect the MTDH expression level. The results revealed that the overexpression of miR‐22 obviously decreased the expression of MTDH (1.081 ± 0.023, P < 0.001).ConclusionInhibition of miR‐22 ameliorated the anticancer drug‐induced cell proliferation decrease in osteosarcoma cells. MTDH was identified as the miR‐22 target in OS cells and MTDH‐triggered autophagy played a key function in the miR‐22‐associated chemotherapy sensitivity.

Highlights

  • Osteosarcoma (OS) is a robust malignant cancer of the bone affecting children and adolescents[1]

  • In the in vitro study, the MTT results indicated that the MG-63 cells with overexpression of miR-22 exhibited a significant decline in the proliferation capacity compared with the control group (0.513 Æ 0.001, P < 0.0005)

  • Similar to the MTT results, MG-63 cells that were transfected with miR-22 mimic (101.0 Æ 10.58) formed fewer colonies compared with the cisplatin group (129.7 Æ 4.163)

Read more

Summary

Introduction

Osteosarcoma (OS) is a robust malignant cancer of the bone affecting children and adolescents[1]. Over the past several decades, application of adjuvant chemotherapy, such as cisplatin, doxorubicin, and methotrexate, has led to a dramatic increase in the survival rate of osteosarcoma[2]. Like most cancers, some patients will develop relapse and chemoresistance. The frequent acquisition of drug resistance is often associated with chemotherapy and is a significant obstacle to achieving a favorable outcome[3]. Studies have demonstrated that numerous mechanisms mediate the development of chemoresistance, including DNA repair[4], altered drug accumulation[5], autophagy-related chemoresistance[6], and micro-RNA (miRNA) dysregulation[7]. To overcome this significant obstacle, research into the mechanism of chemoresistance of OS is important

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call